{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06096675",
            "orgStudyIdInfo": {
                "id": "IRB00095189"
            },
            "organization": {
                "fullName": "Wake Forest University Health Sciences",
                "class": "OTHER"
            },
            "briefTitle": "CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study",
            "officialTitle": "Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis",
            "acronym": "CAPACITY",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "capacity-cardiac-amyloidosis-and-physical-activity-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-17",
            "studyFirstSubmitQcDate": "2023-10-17",
            "studyFirstPostDateStruct": {
                "date": "2023-10-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Wake Forest University Health Sciences",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.",
            "detailedDescription": "The Atrium Health cardiac rehabilitation program delivers a comprehensive approach to improve cardiac performance including supervised exercise programs and has the ideal infrastructure to offer cardio-oncology rehabilitation (CORE) to all our cancer patients in the future. Currently neither CORE nor cardiac rehabilitation for HFpEF are covered by insurance, and hence the targeting of a higher risk cancer and non-cancer population of cardiac amyloidosis patients to objectively measure the benefits of a supervised exercise program ultimately to expand eligibility to all cancer patients and shape the treatment and payor landscape in the future."
        },
        "conditionsModule": {
            "conditions": [
                "Cardiac Amyloidosis"
            ],
            "keywords": [
                "heart failure",
                "preserved ejection fraction",
                "cardiac rehabilitation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Enrollment in supervised cardiac rehabilitation for 3 one-hour sessions a week for a total of 12 weeks (36 sessions)",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "cardiac rehabilitation group",
                    "type": "EXPERIMENTAL",
                    "description": "Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.",
                    "interventionNames": [
                        "Behavioral: \u2022 Cardiac Rehabilitation"
                    ]
                },
                {
                    "label": "control group - no intervention",
                    "type": "NO_INTERVENTION",
                    "description": "Control Group will have baseline 6-minute walk test and CPET testing followed by a repeat 6-minute walk test and CPET test in 12-14 weeks"
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "\u2022 Cardiac Rehabilitation",
                    "description": "Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.",
                    "armGroupLabels": [
                        "cardiac rehabilitation group"
                    ],
                    "otherNames": [
                        "supervised cardiac rehabilitation sessions"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants that complete at least 75% of prescribed cardiac rehab sessions",
                    "description": "Feasibility of cardiac rehab as measured by number of participants that complete at least 75% of prescribed cardiac rehab sessions.",
                    "timeFrame": "Week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in cardiorespiratory fitness - maximal VO2 rates",
                    "description": "Change in cardiorespiratory fitness as assessed by maximal (max) rate (V) of oxygen (O\u2082) your body is able to use during exercise VO2 (ml/kg/min ) on cardiopulmonary exercise test (CPET).\n\nVo2 Max scores can vary based on a number of factors in addition to fitness, such as your gender, age and genetics, but a vo2 max measurement for an average person in their mid 30s to mid 40s is likely to be around: Women - 31 ml oxygen/kg of body weight/minute. Men - 42 ml oxygen/kg of body weight/minute.",
                    "timeFrame": "Week 12"
                },
                {
                    "measure": "Change in cardiorespiratory fitness - Ventilatory Efficiency (VE/VCO2) rates",
                    "description": "Ventilatory equivalent for carbon dioxide ( \u02d9VE/ \u02d9VCO2) identifies the second ventilatory threshold, namely, the point in time when ventilatory drive starts increasing relative to \u02d9VCO2 (i.e., when hyperventilation occurs).",
                    "timeFrame": "Week 12"
                },
                {
                    "measure": "Change in cardiorespiratory fitness - quality of life (KCCQ) Cardiomyopathy Questionnaire (Kansas City) scores",
                    "description": "KCCQ scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent.",
                    "timeFrame": "Week 12"
                },
                {
                    "measure": "Change in cardiorespiratory fitness - chronotropic incompetence scores",
                    "description": "the inability of the heart to increase its rate commensurate with increased activity or demand, is common in patients with cardiovascular disease, produces exercise intolerance which impairs quality-of-life - chronotropic incompetence is usually defined as failure to achieve a chronotropic index of 0.8 or higher (i.e., falling below 97.5 percent of healthy adults).",
                    "timeFrame": "Week 12"
                },
                {
                    "measure": "Change in cardiorespiratory fitness - 6-minute walk test distance",
                    "description": "In healthy subjects, the 6-min walk distance (6MWD) ranges from 400 to 700 m, the main predictor variables being gender, age and height.",
                    "timeFrame": "Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\> 18\n* New York Heart Association (NYHA) Class I-III Heart Failure\n* Able to Exercise\n* On stable treatment for their cardiac amyloidosis or under active surveillance\n* Life expectancy of at least 6 months\n* Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities\n* Participant must be able and willing to follow the cardiac rehabilitation activities\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks\n* NYHA Class IV Heart Failure\n* Pulmonary disease requiring home oxygen\n* Gait instability or history of prior falls\n* In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Dana B Amaro, RN",
                    "role": "CONTACT",
                    "phone": "704-355-4692",
                    "email": "Dana.Amaro@atriumhealth.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jai Singh, MD",
                    "affiliation": "Wake Forest University Health Sciences",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sanger Heart and Vascular Institute",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dana B Amaro, RN",
                            "role": "CONTACT",
                            "phone": "704-355-4692",
                            "email": "Dana.Amaro@atriumhealth.org"
                        },
                        {
                            "name": "Jai Singh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000686",
                    "term": "Amyloidosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000057165",
                    "term": "Proteostasis Deficiencies"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "relevance": "LOW"
                },
                {
                    "id": "M4021",
                    "name": "Amyloidosis",
                    "asFound": "Amyloidosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28747",
                    "name": "Proteostasis Deficiencies",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        }
    },
    "hasResults": false
}